A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.

European Journal of Haematology
Yukiko KimuraMasao Matsuoka

Abstract

CCAAT/enhancer-binding protein α (CEBPA) is an essential transcription factor for myeloid differentiation. Not only mutation of the CEBPA gene, but also promoter methylation, which results in silencing of CEBPA, contributes to the pathogenesis of acute myeloid leukemia (AML). We sought for another differentially methylated region (DMR) that associates with the CEBPA silencing and disease phenotype. Using databases, we identified a conserved DMR in the CEBPA 3'-untranslated region (UTR). Methylation-specific PCR analysis of 231 AML cases showed that hypermethylation of the 3'-UTR was associated with AML that had a myeloid/NK/T-cell phenotype and downregulated CEBPA. Most of these cases were of an immature phenotype with CD7/CD56 positivity. These cases were significantly associated with lower hemoglobin levels than the others. Furthermore, we discovered that the CEBPA 3'-UTR DMR can enhance transcription from the CEBPA native promoter. In vitro experiments identified IKZF1-binding sites in the 3'-UTR that are responsible for this increased transcription of CEBPA. These results indicate that the CEBPA 3'-UTR DMR is a novel regulatory element of CEBPA related to myeloid/NK/T-cell lineage leukemogenesis. Transcriptional regulation ...Continue Reading

References

Nov 1, 1985·The Journal of Experimental Medicine·J KurtzbergM S Hershfield
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·F T LinM D Lane
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Sep 17, 1999·Bioinformatics·T Tsunoda, T Takagi
Dec 11, 2002·British Journal of Haematology·C S ChimY L Kwong
Mar 22, 2003·RNA·Sheila A StewartCarl D Novina
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang-In LinHwei-Fang Tien
Mar 7, 2006·Nature Immunology·Toshimi YoshidaKatia Georgopoulos
Mar 16, 2006·Journal of the National Cancer Institute·Yasuhiro TadaChristoph Plass
Dec 21, 2007·Leukemia·D Caudell, P D Aplan
Dec 26, 2007·Analytical Biochemistry·Mattias D HanssonNick Sirijovski
Apr 11, 2008·Nature·Haruka WadaHiroshi Kawamoto
May 20, 2008·Nucleic Acids Research·Yuichi KumakiMasaki Okano
Jan 9, 2009·The New England Journal of Medicine·Charles G MullighanUNKNOWN Children's Oncology Group
Apr 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Dehua WangAlan D Friedman
Jul 3, 2010·Science·Tomokatsu IkawaHiroshi Kawamoto
Oct 11, 2013·Nature·Annalisa Di RuscioDaniel G Tenen
Sep 30, 2014·Nature Methods·Yassen AssenovChristoph Bock
Feb 15, 2017·Proceedings of the National Academy of Sciences of the United States of America·Yupeng HeJoseph R Ecker
Jun 12, 2018·The Journal of Clinical Investigation·David BoutboulSergio D Rosenzweig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved